US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

32.47

+0.13000.40%

Volume:195

Turnover:6.32K

Market Cap:19.48M

PE:- -

High:32.47

Open:32.47

Low:32.47

Close:32.34

52wk High:33.83

52wk Low:31.18

Shares:600.00K

Float Shares:600.00K

Volume Ratio:0.01

T/O Rate:0.03%

Dividend:0.68

Dividend Rate:2.10%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PWS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":32.47,"timestamp":1791297014914,"preClose":32.34,"halted":0,"volume":195,"delay":0,"changeRate":0.004019789734075308,"floatShares":600000,"shares":600000,"eps":0,"marketStatus":"Trading","change":0.13,"latestTime":"10-06 11:13:54 EDT","open":32.47,"high":32.47,"low":32.47,"amount":6316.732500000001,"amplitude":0,"askPrice":32.42,"askSize":2100,"bidPrice":32.31,"bidSize":1500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791316800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":32.34,"sharesOutstanding":950000,"nav":32.17,"aum":19302000,"dividendRate":0.021001,"bidAskSpread":0.002667,"preHourTrading":{"tag":"盘前","latestPrice":32.13,"preClose":32.34,"latestTime":"08:05 EDT","volume":9,"amount":289.17,"timestamp":1791288316786,"change":-0.21,"changeRate":-0.006494,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":32.34,"preClose":32.34,"latestTime":"16:10 EDT","volume":6,"amount":194.04,"timestamp":1791231005258,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.009706},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":600000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.009706,"shares":600000,"dividePrice":0.6819,"high":32.47,"amplitude":0,"preClose":32.34,"low":32.47,"week52Low":31.18,"pbRate":"--","week52High":33.83,"institutionHeld":0,"latestPrice":32.47,"committee":-0.166667,"eps":0,"divideRate":0.021001,"volume":195,"delay":0,"ttmEps":0,"open":32.47,"prevYearClose":32.3237,"prevWeekClose":32.1643,"prevMonthClose":32.2523,"prevQuarterClose":32.2523,"fiveDayClose":32.2558,"twentyDayClose":33.0172,"sixtyDayClose":32.8116},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"PWS","amount":0.33672,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-03","defaultRemindTime":1788442200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-08","payableDate":"2026-09-03","currency":"USD","dateTimestamp":1788408000000,"payDate":"2026-09-08"},{"date":"2026-06-04","symbol":"PWS","amount":0.0682,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-04","defaultRemindTime":1780579800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-08","payableDate":"2026-06-04","currency":"USD","dateTimestamp":1780545600000,"payDate":"2026-06-08"},{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672309780","title":"Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2672309780","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672309780?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:30","pubTimestamp":1790803800,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3372437/0/en/bright-minds-biosciences-to-participate-in-the-2026-fpwr-research-symposium-and-pws-family-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","FPWR","PWS","BK4139","CNS","DRUG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","IDNA","AARD","BK4007","HYLG","PWS","GDOC","MEDX","BMED","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","IE00BZ1G4Q59.USD","LU0170899867.USD","LU1721428933.USD","LU2237443549.SGD","IE00B1BXHZ80.USD","LU2041044095.USD","LU2746668974.SGD","IE00BKVL7J92.USD","BK4567","BK4505","LU2413666426.HKD","IND","LU2413666699.HKD","LU0149725797.USD","LU2746668461.USD","LENZ","CMC","LU2237443465.HKD","R","LU1721429741.USD","BK4585","BK4232","IE00BHPRN162.USD","BK4139","LU0882574139.USD","LU2237443895.HKD","LU0347712357.USD","LU2229751404.USD","LU2092937221.SGD","IE00BFXG1179.USD","BK4007","LU2237443622.USD","BK4006","LU0971096721.USD","PWS","BK4588","IE00BN0W2W23.USD","BK4121","PSIL","IE00BN0W2T93.GBP","EES","LU2089279066.USD","RLMD","BK4539","IE00BN0W2V16.EUR","LU1721429402.USD","LU1543694498.USD","A","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558874","title":"Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558874?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:01","pubTimestamp":1785841260,"startTime":"0","endTime":"0","summary":"-- U.S. launch of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 n","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338168/0/en/Rhythm-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","BK4201","LU2746668461.USD","PWS","IE00BKVL7J92.USD","LU0170899867.USD","BK4006","EC","LU0149725797.USD","LU0267386448.USD","LU0882574139.USD","CMC","IE00BZ1G4Q59.USD","LU1363072403.SGD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU2237443382.USD","LU2237443622.USD","LU2237443465.HKD","VUS","LU0971096721.USD","IE00BHPRN162.USD","LU2746668974.SGD","LU2237443549.SGD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PWS\",params:#limit:6,delay:false,,,undefined,":[]}}